Oxalyl chloride → N-(4-(tert-Butylamino)quinazolin-8-yl)-2,6-dimethyl-3-(pivalamidomethyl)benzamide
Reaktionsgleichung
[C:1]([NH:5][C:6]1[C:15]2[C:10](=[C:11]([NH2:16])[CH:12]=[CH:13][CH:14]=2)[N:9]=[CH:8][N:7]=1)([CH3:4])([CH3:3])[CH3:2].[CH3:17][C:18]1[C:26]([CH2:27][NH:28][C:29](=[O:34])[C:30]([CH3:33])([CH3:32])[CH3:31])=[CH:25][CH:24]=[C:23]([CH3:35])[C:19]=1[C:20](O)=[O:21].C(Cl)(=O)C(Cl)=O.CCN(C(C)C)C(C)C>CN(C=O)C.C(Cl)Cl>[C:1]([NH:5][C:6]1[C:15]2[C:10](=[C:11]([NH:16][C:20](=[O:21])[C:19]3[C:23]([CH3:35])=[CH:24][CH:25]=[C:26]([CH2:27][NH:28][C:29](=[O:34])[C:30]([CH3:31])([CH3:32])[CH3:33])[C:18]=3[CH3:17])[CH:12]=[CH:13][CH:14]=2)[N:9]=[CH:8][N:7]=1)([CH3:4])([CH3:2])[CH3:3]Komponenten
7
Edukt 4
Produkt 1
Reagenzien, Katalysatoren, Lösungsmittel 2
Versuchsvorschrift
The title compound was prepared following the procedure described in Example-1 using N4-(tert-butyl)quinazoline-4,8-diamine (Intermediate-55, 275 mg, 1.27 mmol), 2,6-dimethyl-3-(pivalamidomethyl)benzoic acid (Intermediate-4, 401 mg, 1.52 mmol), oxalyl chloride (230 mg, 1.82 mmol), DMF (1 drop) and DIPEA (392 mg, 3.04 mmol) in CH2Cl2 (10 mL) to afford 30 mg of the title product. 1H NMR (300 MHz, DMSO-d6): δ 9.68 (s, 1H), 8.70-8.67 (d, J=7.8 Hz, 1H), 8.44 (s, 1H), 8.13-8.10 (d, J=8.4 Hz, 1H), 7.94 (t, 1H), 7.49-7.43 (m, 2H), 7.13-7.11 (m, 2H), 4.23 (d, 2H), 2.24 (s, 3H), 2.21 (s, 3H), 1.52 (s, 9H), 1.12 (s, 9H); MS [M+H]+: 462.44.
Aufarbeitung
- customThe title compound was prepared
Quellen und Nachweise
- ORD-Eintrag
- ord-2e11993484e645a89737fe1933de86b6
- Quelldatensatz
- uspto-grants-2015_04
- Patentnummer
- US09006257B2
Notizen zur Reaktion
Wird geladen…